Exploring genetic therapies for LAMA2 congenital muscular dystrophy
Therapeutic genetics and disease modeling in LAMA2-CMD
This study is exploring a new way to help young children with LAMA2 congenital muscular dystrophy by using a special gene-editing tool to fix the genetic problems in their muscles, with the hope of making them stronger and improving their quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11090332 on NIH RePORTER |
What this research studies
This research focuses on LAMA2 congenital muscular dystrophy (LAMA2-CMD), a severe genetic condition affecting young children. It aims to develop genetic therapies using CRISPR technology to correct mutations in the LAMA2 gene, which is crucial for muscle function. The approach involves using adeno-associated viral vectors to deliver therapeutic genes directly to affected muscle cells, potentially reversing the disease's progression. By studying various mutations, the research seeks to find effective treatments that could improve muscle health and overall quality of life for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old diagnosed with LAMA2 congenital muscular dystrophy.
Not a fit: Patients with muscular dystrophies caused by mutations in genes other than LAMA2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking genetic therapies that restore muscle function in children with LAMA2-CMD.
How similar studies have performed: Previous research using CRISPR technology for genetic correction in animal models has shown promising results, indicating potential for success in human applications.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Vockley, Gerard — University of Pittsburgh at Pittsburgh
- Study coordinator: Vockley, Gerard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.